BRCA1 and ovarian serous adenocarcinoma: It has been estimated that approximately half of high-grade serous ovarian adenocarcinoma samples are defective in HR repair pathway, and these HR defects are largely driven by mutations or epigenetic silencing of BRCA1 and BRCA2 genes [27].